Shanghai Chest Hospital
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1957-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
164
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (129 trials with phase data)• Click on a phase to view related trials
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
- Conditions
- Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: Osimertinib-based adaptive treatment
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT07058519
- Locations
- 🇨🇳
Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Optical Biopsy and Cytological Evaluation for Intrathoracic Lymphadenopathy
- Conditions
- Intrathoracic Lymphadenopathy
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT07047417
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Assessment the Effectiveness of BTVA in COPD and Ablation in Pulmonary Nodules by Pulmonary MRI
- Conditions
- COPDLung Cancers
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT07045532
- Locations
- 🇨🇳
Shanghai chest hospital, Shanghai, Shanghai, China
The Novel Special Light for Endotracheal/Bronchial Lesions.
- Conditions
- Tracheal DiseaseBronchial Disease
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT07036614
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
- Conditions
- EGFR Mutation Positive Advanced Non Small Cell Lung CancerPD-L1 Positive
- Interventions
- Drug: Limertinib+bevacizumab
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 136
- Registration Number
- NCT06982924
- Prev
- 1
- 2
- 3
- 4
- 5
- 33
- Next
News
Everest Medicines Advances AI-Powered mRNA Platform with Cancer Vaccine Breakthroughs
Everest Medicines unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day, showcasing a fully integrated system spanning antigen design to manufacturing.
Chinese Drug Combination Outperforms Keytruda in Advanced Lung Cancer Trial
A Chinese-developed drug combination of Benmelstobart and Anlotinib demonstrated superior efficacy over pembrolizumab (Keytruda) in treating PD-L1-positive advanced non-small cell lung cancer patients.
Shanghai Chest Hospital to Initiate CAR-T Therapy Trial for Lung Cancer
Shanghai Chest Hospital will begin a clinical trial in January to assess a novel CAR-T cell therapy for lung cancer, aiming to enroll 20 patients in the first phase.